首页> 外文期刊>Journal of clinical gastroenterology >Coupled plasma filtration adsorption combined with continuous veno-venous hemofiltration treatment in patients with severe acute pancreatitis
【24h】

Coupled plasma filtration adsorption combined with continuous veno-venous hemofiltration treatment in patients with severe acute pancreatitis

机译:重症急性胰腺炎患者血浆滤过吸附联合连续静脉血液滤过治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Severe acute pancreatitis (SAP) still has a high mortality rate. Coupled plasma filtration adsorption (CPFA) and continuous veno-venous hemofiltration (CVVH) are 2 extracorporeal blood purification techniques. We hypothesized that CPFA combined with CVVH could preferentially improve prognosis and suppress clinical manifestations of SAP. Background: In this observational cohort study, 25 patients with SAP were enrolled, in which 12 received CPFA plus CVVH treatment (group 1), and 13 received CVVH therapy (group 2). All the patients underwent a successive 10-day intervention. Clinical indicators were detected before or after the intervention and the results were compared between the 2 groups. The feasibility and the survival rate were evaluated on day 28. Results: Compared with group 2, oxygenation index (PaO2/FiO2), mean arterial pressure, serum amylase, and blood urine nitrogen showed significant differences (all P<0.01) and serum TNF-α, IL-1β, IL-6 were reduced and IL-10 was elevated with time in group 1 (all P<0.01). Liver functions, electrolyte, and acid-base balance did not show significant difference before and after the 10-day treatment with CPFA plus CVVH compared with CVVH (P>0.05). No therapy-related adverse reactions were noted in both groups. Twenty-eight-day survival rate of group 1 was higher than that in group 2 [91.7% (11/12) vs. 53.8% (7/13), P<0.05]. Conclusions: CPFA combined with CVVH was an effective and safe method for treatment of SAP patients, the mechanism being related to its effect on regulating the level of cytokines and serum amylase.
机译:背景:重症急性胰腺炎(SAP)仍然具有很高的死亡率。耦合血浆过滤吸附(CPFA)和连续静脉血液滤过(CVVH)是2种体外血液净化技术。我们假设CPFA联合CVVH可以优先改善SAP的预后并抑制其临床表现。背景:在这项观察性队列研究中,招募了25例SAP患者,其中12例接受CPFA加CVVH治疗(第1组),而13例接受CVVH治疗(第2组)。所有患者均接受了连续10天的干预。在干预之前或之后检测临床指标,并比较两组的结果。在第28天评估可行性和存活率。结果:与第2组相比,氧合指数(PaO2 / FiO2),平均动脉压,血清淀粉酶和血尿氮显示出显着差异(所有P <0.01)和血清TNF第1组中-α,IL-1β,IL-6降低,IL-10升高(均P <0.01)。与CVVH相比,CPFA加CVVH治疗10天前后,肝功能,电解质和酸碱平衡均无显着差异(P> 0.05)。两组均未发现与治疗相关的不良反应。第1组的28天生存率高于第2组[91.7%(11/12)对53.8%(7/13),P <0.05]。结论:CPFA联合CVVH是治疗SAP患者的一种安全有效的方法,其机制与其对细胞因子和血清淀粉酶水平的调节有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号